Pazopanib
- Generic Name
- Pazopanib
- Brand Names
- Votrient
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N7O2S
- CAS Number
- 444731-52-6
- Unique Ingredient Identifier
- 7RN5DR86CK
- Background
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
- Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 58
- Registration Number
- NCT00619424
- Locations
- 🇮🇹
GSK Investigational Site, Orbassano (TO), Piemonte, Italy
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT00612456
- Locations
- 🇮🇹
GSK Investigational Site, Padova, Veneto, Italy
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
- Conditions
- TumorEpithelial Ovarian CancerCervix DiseasesPrimary Peritoneal CarcinomaCancerUterine DiseaseNeoplasms, Ovarian
- Interventions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2012-03-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00561795
- Locations
- 🇩🇪
GSK Investigational Site, Essen, Nordrhein-westfalen, Germany
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 163
- Registration Number
- NCT00558103
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, United Kingdom
Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2007-10-25
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT00549328
- Locations
- 🇺🇸
GSK Investigational Site, Seattle, Washington, United States
Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer
- Conditions
- Neoplasms, Colorectal
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT00540943
- Locations
- 🇫🇷
GSK Investigational Site, Toulouse, France
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00516672
- Locations
- 🇯🇵
GSK Investigational Site, Saitama, Japan
Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer
- Conditions
- Stage IV Breast CancerRecurrent Breast CancerBreast Cancer
- Interventions
- Procedure: pharmacological studyProcedure: laboratory biomarker analysis
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00509587
- Locations
- 🇨🇦
BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦The Ottawa Hospital Cancer Centre (Ottawa Health Research Institute) Civic Campus, Ottawa, Ontario, Canada
Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
- Conditions
- Hormone-Resistant Prostate CancerRecurrent Prostate Carcinoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2007-06-14
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 23
- Registration Number
- NCT00486642
- Locations
- 🇨🇦
Ottawa Hospital and Cancer Center-General Campus, Ottawa, Ontario, Canada
🇨🇦London Regional Cancer Program, London, Ontario, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
- Conditions
- Distal Urethral CancerProximal Urethral CancerRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerStage IV Bladder CancerTransitional Cell Carcinoma of the BladderUrethral Cancer Associated With Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2007-05-10
- Last Posted Date
- 2014-05-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT00471536
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇨🇳Chinese University of Hong Kong-Prince of Wales Hospital, Shatin, Hong Kong, China
🇺🇸Cox Medical Center, Springfield, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.